Axsome Therapeutics, Inc. (AXSM)
After hours:
Chart Events
Performance Outlook
| Previous Close | 24.75 |
| Open | 25.18 |
| Bid | 24.01 x 1200 |
| Ask | 24.67 x 1000 |
| Day's Range | 23.85 - 25.32 |
| 52 Week Range | 19.38 - 74.10 |
| Volume | |
| Avg. Volume | 1,120,985 |
| Market Cap | 921.939M |
| Beta (5Y Monthly) | 2.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.35 |
| Earnings Date | Feb 28, 2022 - Mar 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 81.21 |
- GlobeNewswire
Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event
NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will host a virtual event on Tuesday, June 28, 2022 at 9:00 AM EDT to provide investors an update on Sunosi® (solriamfetol). Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in ad
- Motley Fool
3 Stocks That Could Double by 2025
Here's why they chose Axsome Therapeutics (NASDAQ: AXSM), Jazz Pharmaceuticals (NASDAQ: JAZZ), and Twist Bioscience (NASDAQ: TWST). Prosper Junior Bakiny (Axsome Therapeutics): Investors intent on doubling their money by 2025 might benefit from looking at stocks that seem wildly undervalued and could experience multiple catalysts in the next couple of years. Axsome Therapeutics lagged the market in recent months, primarily because of regulatory roadblocks.
- Motley Fool
2 Top Biotech Stocks Ready for Bull Runs
Let's look at two stocks that could rebound from their recent woes in the market: Axsome Therapeutics (NASDAQ: AXSM) and CRISPR Therapeutics (NASDAQ: CRSP). Few things can wreak more havoc on biotech companies than regulatory rejections for their leading pipeline candidates. The company's shares have been hammered over the past year because it failed to earn regulatory approval for its two leading products.
